| Date Filed | Type | Description |
| 08/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Company” or “Innoviva”) and you regarding the details of your employment with the Company. Your employment with the Company hereunder will commence on a date mutually agreeable to you and the Company, but in all events no later than August 21, 2023 (the date on which your employment commences being, the “Commencement Date",
"Innoviva Appoints Stephen Basso as Chief Financial Officer BURLINGAME, Calif., August 25, 2023 – Innoviva, Inc. , a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. “We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “I look forward to working with Stephen to advance our strategy and create shareholder value.” Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical industry. Prior to joining Innoviva, Mr. Basso served a..." |
|
| 08/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
| 07/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/24/2023 |
8-K
| Investor presentation |
| 05/23/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/15/2023 |
SC 13D/A
| Sarissa Capital Management LP reports a 10.5% stake in Innoviva, Inc. |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/20/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G
| PUTNAM INVESTMENTS LLC reports a 7.6% stake in INNOVIVA INC |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| BlackRock Inc. reports a 15.2% stake in INNOVIVA INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.1% stake in Innoviva Inc. |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.6% stake in INNOVIVA INC |
| 01/10/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
| 01/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
8-K/A
| Quarterly results |
| 09/14/2022 |
8-K
| Investor presentation |
| 08/23/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/22/2022 |
8-K
| Quarterly results |
| 08/22/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/16/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 07/27/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/27/2022 |
8-K
| Quarterly results |
| 07/25/2022 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
|